Developing an objective marker to optimize patient selection and predict survival benefit in early‐phase cancer trials
Chara Stavraka(King's College London), Sarah P. Blagden(Churchill Hospital), Séan M. O’Cathail(Imperial College London), Michael J. Seckl(Charing Cross Hospital), Sayed Babar(Imperial College Healthcare NHS Trust), Martin Förster, Rebecca Kristeleit(Guy's and St Thomas' NHS Foundation Trust), David J. Pinato(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Samantha Turnbull(University College London), Michael Flynn(Henry Ford Health System)
Cited by 19
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer
|JAMA Oncology|2019|582